Opendata, web and dolomites

DEMABIS SIGNED

Democratizing Machine Learning for Big Series

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "DEMABIS" data sheet

The following table provides information about the project.

Coordinator
GRUMPY CAT SOFTWARE SL 

Organization address
address: C/ PUERTA DEL MAR 18, 2 PLANTA
city: MALAGA
postcode: 29005
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GRUMPY CAT SOFTWARE SL ES (MALAGA) coordinator 50˙000.00

Map

 Project objective

Shapelets is the first state-of-the-art Data Series Management System. A Machine Learning platform that empowers users to obtain invaluable insights from their time series data in a way that no other tool or platform in the market does. Our innovation comes not only from a holistic and unique approach to time series data management but also from the implementation of recently discovered novel algorithms for time series data. We are a 100% private owned company focused on R&D. We have a cohesive and highly-skilled team, where half of the employees know each other from a previous company and where leadership and management excel from a technical and business point of view. We are currently 7 people and plan to hire an average of 11 people each year to reach 52 by the end of 2023. Our main verticals and use cases are in the following sectors: Energy, Industrial IoT, Aerospace, Automotive, Health, Sports and Financial. The major market barrier now is to reach critical mass with Shapelets as quickly as possible — a necessity for us given the novelty behind the idea. Our investment plan for for this market opportunity involves obtaining €2M from VCs in 2019 and a another €2M from VCs in 2020. With this funding we will be able to grow our team fast enough to launch the first full and free version of our product, promote our open-source platform so it becomes a standard for time-series analysis and continue building the different industry verticals. We project to triple our revenue to 1.4€M in 2021 and double it in 2022 and 2023. We expect to start making profits from this project by the end of 2021 and a net income is projected to reach €1.15M in 2022 as sales increase and operations become more efficient. With this funding application we pretend to generate a feasibility study to get a grip on the R&D, technical feasibility and commercial potential of our disruptive technology in order to capture this into a business plan for scaling it up.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DEMABIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DEMABIS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Nocturne (2019)

The eye as a window to the brain, extending lifelong brain health

Read More  

NextGen-O2k (2019)

Next Generation Instrument for In-Depth Analysis of Mitochondrial Fitness

Read More  

PD-Watch (2019)

Wearable technology for the selective detection and continuous monitoring of movement disorders related to Parkinson’s disease

Read More